REFERENCES
1. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723-50.
2. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology 2014;272:635-54.
3. Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 2018;289:816-30.
4. Kim TS, Pak JH, Kim JB, Bahk YY. Clonorchis sinensis, an oriental liver fluke, as a human biological agent of cholangiocarcinoma: a brief review. BMB Rep 2016;49:590-7.
5. Huang Y, Chen W, Wang X, et al. The carcinogenic liver fluke, Clonorchis sinensis: new assembly, reannotation and analysis of the genome and characterization of tissue transcriptomes. PLoS One 2013;8:e54732.
6. Koda S, Zhu XQ, Zheng KY, Yan C. Molecular mechanisms of clonorchis sinensis-host interactions and implications for vaccine development. Front Cell Dev Biol 2021;9:781768.
7. Yang QL, Lu XW, Fang ZL, et al. The association between Clonorchis sinensis seropositivity and hepatocellular carcinoma in an endemic area: a study in Guangxi, China. BMC Infect Dis 2025;25:270.
8. Lin Q, Tang Z, Qin Y, et al. Clonorchis sinensis infection amplifies hepatocellular carcinoma stemness, predicting unfavorable prognosis. PLoS Negl Trop Dis 2024;18:e0011906.
9. Chen J, Wei C, Huang W, et al. Clonorchis sinensis-infected hepatocellular carcinoma exhibits distinct tumor microenvironment and molecular features. Front Immunol 2025;16:1526699.
10. Liu JQ, Wang J, Huang XL, et al. A radiomics model based on magnetic resonance imaging to predict cytokeratin 7/19 expression and liver fluke infection of hepatocellular carcinoma. Sci Rep 2023;13:17553.
11. Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 2012;48:441-6.
12. Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006.
13. Lambin P, Leijenaar RTH, Deist TM, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 2017;14:749-62.
14. Ji GW, Zhu FP, Xu Q, et al. Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: a multi-institutional study. EBioMedicine 2019;50:156-65.
15. Ji GW, Zhu FP, Xu Q, et al. Radiomic features at contrast-enhanced CT predict recurrence in early stage hepatocellular carcinoma: a multi-institutional study. Radiology 2020;294:568-79.
16. Park HJ, Kim JH, Choi SY, et al. Prediction of therapeutic response of hepatocellular carcinoma to transcatheter arterial chemoembolization based on pretherapeutic dynamic CT and textural findings. AJR Am J Roentgenol 2017;209:W211-20.
17. Chen Y, Xia Y, Tolat PP, et al. Comparison of conventional gadoxetate disodium-enhanced MRI features and radiomics signatures with machine learning for diagnosing microvascular invasion. AJR Am J Roentgenol 2021;216:1510-20.
18. Feng ST, Jia Y, Liao B, et al. Preoperative prediction of microvascular invasion in hepatocellular cancer: a radiomics model using Gd-EOB-DTPA-enhanced MRI. Eur Radiol 2019;29:4648-59.
19. Wang Q, Sheng Y, Jiang Z, Liu H, Lu H, Xing W. What imaging modality is more effective in predicting early recurrence of hepatocellular carcinoma after hepatectomy using radiomics analysis: CT or MRI or both? Diagnostics 2023;13:2012.
20. Castaldo A, De Lucia DR, Pontillo G, et al. State of the art in artificial intelligence and radiomics in hepatocellular carcinoma. Diagnostics 2021;11:1194.
21. Harding-Theobald E, Louissaint J, Maraj B, et al. Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma. Aliment Pharmacol Ther 2021;54:890-901.
22. Brancato V, Cerrone M, Garbino N, Salvatore M, Cavaliere C. Current status of magnetic resonance imaging radiomics in hepatocellular carcinoma: a quantitative review with Radiomics Quality Score. World J Gastroenterol 2024;30:381-417.
23. Bernatowicz K, Grussu F, Ligero M, Garcia A, Delgado E, Perez-Lopez R. Robust imaging habitat computation using voxel-wise radiomics features. Sci Rep 2021;11:20133.
24. Fang M, Kan Y, Dong D, et al. Multi-habitat based radiomics for the prediction of treatment response to concurrent chemotherapy and radiation therapy in locally advanced cervical cancer. Front Oncol 2020;10:563.
25. Shang Y, Zeng Y, Luo S, et al. Habitat imaging with tumoral and peritumoral radiomics for prediction of lung adenocarcinoma invasiveness on preoperative chest CT: a multicenter study. AJR Am J Roentgenol 2024;223:e2431675.
26. Shan QY, Hu HT, Feng ST, et al. CT-based peritumoral radiomics signatures to predict early recurrence in hepatocellular carcinoma after curative tumor resection or ablation. Cancer Imaging 2019;19:11.
27. Zhang Y, Wang S, Song M, et al. MRI-based intra- and peritumoral heterogeneity in hepatocellular carcinoma for microvascular invasion prediction and prognostic risk stratification. Radiol Imaging Cancer 2025;7:e250066.
28. Isensee F, Jaeger PF, Kohl SAA, Petersen J, Maier-Hein KH. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. Nat Methods 2021;18:203-11.
29. van Griethuysen JJM, Fedorov A, Parmar C, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res 2017;77:e104-7.
30. Zwanenburg A, Vallières M, Abdalah MA, et al. The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology 2020;295:328-38.
